Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 26Salivary Gland Neoplasms 2Metastatic Castration-resistant Prostate Cancer 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Neoplasm Metastasis 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Carcinoma, Intraductal, Noninfiltrating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Female 1Biochemically Recurrent Prostate Cancer 1Adenocarcinoma 1

Interventions

bicalutamide 4pembrolizumab 1nilutamide 1exemestane 1darolutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bulbo-Spinal Atrophy, X-Linked × darolutamide × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡